Unmet need in chronic hepatitis B management
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucle...
Main Authors: | Lilian Yan Liang, Grace Lai-Hung Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2019-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2018-0106.pdf |
Similar Items
-
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01) -
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
by: Kento Inada, et al.
Published: (2021-09-01) -
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01) -
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01) -
Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC
by: Charing Ching-Ning Chong, et al.
Published: (2016-03-01)